Johnson & Johnson AI Strategy: From 900 Experiments to a Few Big Bets
How Johnson & Johnson uses AI on its own work: 900 generative AI use cases cut to a few priorities, function-led governance and faster drug discovery. Updated November 2026.
Innovative medicines and medical technology, including surgery, orthopaedics and cardiovascular devices
J&J has no standalone AI strategy document. Its approach comes from CIO interviews in 2025 and 2026 and a September 2026 company page.
Read the company sourceWhere Johnson & Johnson Is Going with AI
Johnson & Johnson cut about 900 generative AI use cases down to a few priorities that create most of the value. Chief Information Officer Jim Swanson told The Wall Street Journal in April 2025 that only 10% to 15% of use cases delivered about 80% of the value.
The pivot followed a year of open experimentation. Swanson said: “Now we’ve moved from the thousand flowers to a really prioritized focus on GenAI.” Lead with AI looked at what other leaders can learn from this shift in why the best AI strategy starts with a thousand experiments.
Focus is still the message in 2026. Swanson said on a September 2026 company page: “At J&J, we are applying AI in prioritized areas that deliver the highest value.” J&J has no standalone AI strategy document, so this profile draws on interviews and company pages.
The focus has four parts.
- Drug discovery and development: AI that screens and optimizes drug leads
- Clinical trials: AI that finds trial sites and participants and prepares trial documents for regulators
- Supply chain and manufacturing: AI that spots supply risks and times manufacturing steps
- Sales: Rep Copilot, which coaches sales representatives on how to engage health care professionals
What It Takes: Function-Led Governance, Digital Talent and Training
The business functions now decide which AI projects continue. J&J removed the central board that vetted employee generative AI ideas and gave governance to functions such as commercial, supply chain and research. They can shut down or merge duplicate projects and move resources to those that work.
J&J has a large digital workforce to build this. It employs nearly 7,000 digital specialists and data scientists, according to its September 2026 company page.
Training came before access. In 2024, J&J required employees to complete a generative AI course before using generative AI, and about 20,000 had taken one (Fortune, April 2024). Employees had also completed nearly 30,000 courses in a digital boot camp on AI, automation and data.
Every role is mapped to skills. J&J’s learning team linked each job to the skills it needs, and an AI-driven system recommends upskilling paths to employees (CDO Magazine, March 2025).
J&J frames AI as an added skill. Swanson told Reuters in April 2026: “A software engineer isn’t getting replaced, now their role is expanding.” He added: “These are ‘and’ skills, not ‘or’ skills.”
AI fluency, coded against the Lead with AI Fluency Matrix (September 2026 edition):
- Fluency floor: Level 1, set by an access rule. In 2024, J&J required a generative AI course before employees could use generative AI. J&J has not published a newer standard.
- Highest level evidenced: Level 3 (Integrating), company-claimed. AI is built into drug discovery and regulatory writing, where Swanson says clinical trial report preparation fell from 700 to 900 hours to about 15 minutes. These figures have not been independently verified.
- Portfolio design: J&J concentrates on a few priorities in drug development, supply chain and AI-enabled products, and each function decides what to fund.
How Johnson & Johnson Measures Results
J&J tracks deployment, adoption and business outcomes for its AI priorities, according to the 2025 Wall Street Journal report. It reports results by use case, and all figures below are company-claimed:
- Drug discovery: lead optimization time cut in half, speeding two drug candidates, one in oncology and one in immunology
- Regulatory writing: clinical trial report preparation down from 700 to 900 hours to about 15 minutes
- Portfolio: 10% to 15% of use cases delivering about 80% of the value
Gaps remain. J&J gives no dollar figure for the value of AI across the company. Linking use-case results to cost and growth is the step from AI adoption to AI value.
Next markers: results from Rep Copilot in medical technology, a company-wide value figure, an updated training standard and headcount for 2026.
Change log
- April 2024: J&J requires a generative AI course before employees use generative AI.
- April 2025: J&J says it has narrowed about 900 generative AI use cases to its priorities.
- April 2026: Swanson says AI has cut lead optimization time in half.
- September 2026: J&J says it applies AI in prioritized areas that deliver the highest value.
The Bottom Line
- Disclosure: 4 of 4. J&J answers all four questions, and it measures results by use case without a total.
- Focus is the strategy. J&J cut about 900 use cases to the few that create most of the value.
- Functions own the decisions after J&J removed its central AI board.
- Level 3 is evidenced in drug discovery and regulatory writing, on company-claimed results.
- The say-do gap is the total. J&J says it focuses on value but publishes no company-wide figure.
- Watch the pipeline. The test is whether faster lead optimization brings new medicines to patients sooner.
Revenue, Headcount and Revenue per Employee
What the numbers show: Revenue rose 11% from fiscal 2023 to fiscal 2025 while headcount rose 5%, so revenue per employee rose 6%, to about $682,000. The series starts in 2023 because J&J separated its consumer health business, Kenvue, that year. These figures do not show that AI caused any change.
Revenue, headcount and revenue per employee, FY2023 to FY2025
- FY2023: $85.16bn revenue, 131,900 employees, $646k per employee
- FY2024: $88.82bn revenue, 138,100 employees, $643k per employee
- FY2025: $94.19bn revenue, 138,200 employees, $682k per employee
Change, FY2023 to FY2025: revenue up 11%, headcount up 5%, revenue per employee up 6%.
Notes: Revenue is sales to customers, as reported. Headcount is approximate, at fiscal year-end. The series starts in fiscal 2023 because J&J separated its consumer health business, Kenvue, in 2023, and fiscal 2022 headcount includes Kenvue staff. J&J is also preparing to separate its orthopaedics business.
These figures give context on scale and productivity. They do not show that AI caused any change. Sources: Johnson & Johnson 10-K filings.
How Johnson & Johnson Compares with US Pharma Peers
We looked at how Johnson & Johnson compares with other US pharmaceutical companies in the index. Here is how they stack up.
| Company | Disclosure | AI owner | Fluency floor | Governance | AI value reported | Revenue per employee |
|---|---|---|---|---|---|---|
| AbbVie | 4 of 4 | VP of AI Strategy and Partnerships | Not published; training offered at all levels | Human expertise and ethical use; no published framework | One result (regulatory writing), no total | $1.07M |
| Amgen | 3 of 4 | EVP of research, AI and data; SVP and CTO | Not published; ChatGPT Enterprise across the company | Published AI Vision; phased rollouts | None published | $1.17M |
| Bristol Myers Squibb | 4 of 4 | EVP and Chief Digital and Technology Officer | Not published; frontier models for all staff | Enterprise governance and audit controls; humans decide | Targets set, no results | $1.48M |
| Eli Lilly | 3 of 4 | Chief AI Officer | Level 1, by expectation | Eight principles, board briefings | No: capacity and deals | $1.30M |
| Gilead Sciences | 2 of 4 | Global CIO; no AI leader named | Not published; AI coach in pilot | Six published AI principles | None published | $1.73M |
| Johnson & Johnson | 4 of 4 | EVP and CIO; each function governs its own AI | Level 1, training required before access (2024) | Function-led governance; central AI board removed | Results by use case, no total | $682k |
| Merck | 4 of 4 | CEO sponsors five AI programs; CIO leads technology | Not published; 80%+ use the AI platform | Human review of AI drafts; no published framework | Results by use case, no total | $867k |
| Pfizer | 3 of 4 | Chief AI, Data and Analytics Officer | Level 1, 98% trained | Three principles, a board risk topic | Inside wider cost programs | $834k |
| Moderna AI Pacesetter | 2 of 4 | Chief People and Digital Technology Officer | Level 1, by expectation | Mentioned, not described | No: adoption figures | $414k |
Disclosure counts how many of the four strategy questions (where it is going, where it will focus, what it will take and how it will know it is working) a company answers in public. Fluency floor is the lowest level of AI fluency a company expects of all its people, on the five levels of the Lead with AI Fluency Matrix: Avoiding (0), Chatting (1), Collaborating (2), Integrating (3) and Transforming (4). The other columns summarize each company’s profile. Revenue per employee is for each company’s latest fiscal year, in US dollars. Rows marked AI Pacesetter or Notable are companies outside the S&P 100 and STOXX Europe 50. They are shown for contrast and are not counted in any index figure. See all companies in the AI Strategy Index.
Frequently Asked Questions
What is Johnson & Johnson’s AI strategy for its own work?
J&J focuses AI on a few priorities in drug development, supply chain and AI-enabled products. It narrowed about 900 generative AI use cases to the ones that create most of the value.
Who leads AI at Johnson & Johnson?
Executive Vice President and Chief Information Officer Jim Swanson leads J&J’s AI work, under Chairman and CEO Joaquin Duato. Business functions govern their own AI projects.
Do J&J employees need AI training?
In 2024, J&J required a generative AI course before employees could use generative AI. About 20,000 workers had taken one by then.
Is Johnson & Johnson cutting jobs because of AI?
The sources reviewed show no AI-linked job cuts at J&J. Swanson says AI expands roles, and headcount was about 138,200 at the end of 2025.
How is this profile put together?
Lead with AI profiles use public sources only, such as annual reports, earnings materials, filings and on-record interviews, dated at the time of writing. AI fluency is coded against the Lead with AI Fluency Matrix, and company figures are marked as company-claimed unless they have been independently verified.
About the AI Strategy Index
The Lead with AI AI Strategy Index profiles how the largest companies in the US and Europe approach AI, starting with the S&P 100 and the STOXX Europe 50. Each profile answers four questions: where the company is going with AI, where it will focus, what it will take and how it will know it is working. AI Pacesetters and notable companies outside the two indexes are profiled for contrast and are not counted. Profiles use public sources only, and AI fluency is coded against the Lead with AI Fluency Matrix.
See all company profiles